Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kazia Therapeutics Ltd (KZA.AX)

Kazia Therapeutics Ltd (KZA.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kazia Therapeutics Ltd 300 Barangaroo Avenue Level 24 Sydney NSW 2000 AUS

https://www.kaziatherapeutics.com P: +61 294724101 F: +61 294760388

Description:

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Key Statistics

Overview:

Market Capitalization, $K 18,908
Shares Outstanding, K 236,349
Annual Sales, $ 2,308 K
Annual Net Income, $ -26,778 K
Last Quarter Sales, $ 2,898 K
Last Quarter Net Income, $ -4,370 K
% of Institutional Shareholders 5.95%

Growth:

1-Year Return -19.19%
3-Year Return -94.90%
5-Year Return -78.95%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.11
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 11/17/17

KZA.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -2,634.33%
Return-on-Assets % -107.83%
Profit Margin % -1,160.23%
Debt/Equity N/A
Price/Sales N/A
Price/Book 1.57
Book Value/Share 0.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar